Wednesday, October 21, 2015 4:59:04 PM
http://www.nature.com/articles/srep15259
this paper just up on nature journal discussing possible cure for HBV using multi-shRNA vector delivery, on the back of their mice study. It includes Suhy's 2012 paper as a reference (40). Authors out of Taiwan, US, and China institutes.
Selection of escape mutants with mutations within the target sequence could abolish the antiviral RNA interference activity. Here, we investigated the impact of a pre-existing shRNA-resistant HBV variant on the efficacy of shRNA therapy. ..
..In contrast, combinatorial therapy using S1 and P28, one of six potent shRNAs, markedly reduced titers for both wild-type and T472C HBV. Interestingly, treatment with P28 alone led to the emergence of escape mutants with mutations in the P28 target region. Our results demonstrate that combinatorial RNAi therapy can minimize the escape of resistant viral mutants in chronic HBV patients.
In this study, we used two AAV vectors each expressing a different shRNA for the combinatorial therapy. For convenience, one can simultaneously express multiple shRNAs in a single viral vector by combining multiple shRNA-expression cassettes containing the same or different promoters23,40. Alternatively, one can also apply long hairpin RNAs25 or polycistronic microRNAs41 to generate multiple siRNAs in a single cell. These novel delivery vectors, in particular the one with the microRNA backbone, may further improve the safety profiles in vivo by reducing siRNA transcription but still maintaining their silencing activity. In this regard, the combinatorial use of a multiple shRNA-delivery vector and the highly potent shRNAs identified in this study might provide a potential cure for, or long term management of, chronic HBV infection.
All my posts, comments, and investments are not to be considered investment advice in any way.
Recent BNTC News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/06/2024 05:15:18 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 09:19:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/21/2023 12:05:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/21/2023 12:00:53 PM
- Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 09:26:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 09:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:01:00 PM
- Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering • GlobeNewswire Inc. • 08/11/2023 05:00:12 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM